비교리스트

 카트 문의
시장보고서
상품코드
1655415

세계의 수막염균 백신 시장

Meningococcal Vaccines
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 194 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 수막염균 백신 시장은 2030년까지 54억 달러에 도달

2024년에 41억 달러로 추정되는 세계의 수막염균 백신 시장은 2024-2030년의 분석 기간에 CAGR 4.8%로 성장하며, 2030년에는 54억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 4가 백신은 CAGR 5.1%를 기록하며, 분석 기간 종료시에는 31억 달러에 달할 것으로 예측됩니다. 2가 백신 부문의 성장률은 분석 기간 중 CAGR 4.6%로 추정됩니다.

미국 시장은 11억 달러, 중국은 CAGR 4.5%로 성장할 것으로 예측

미국의 수막염균 백신 시장은 2024년에 11억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 8억 4,970만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 4.5%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.7%와 3.8%로 예측됩니다. 유럽에서는 독일이 CAGR 4.1%로 성장할 것으로 예측됩니다.

세계 수막구균 백신 시장 - 주요 동향 및 촉진요인 정리

수막염균 백신이란 무엇이며, 왜 중요한가?

수막염균 백신은 수막염 및 기타 심각한 감염을 유발하는 수막염균과 싸우는 백신입니다. 이 백신은 특히 세균성 수막염이 유행하는 지역에서 이러한 치명적인 질병을 예방하는 중요한 공중보건 수단입니다. 수막구균 백신은 다양한 제형으로 제공되며, 여러 혈청군의 수막구균을 예방함으로써 다양한 인구 집단에 대한 면역의 폭을 넓혀줍니다. 수막구균성 질환은 빠르게 발병하고 심각해지는 것으로 알려져 있으므로 이 백신은 생명을 구할 뿐만 아니라 이러한 감염성 질환을 치료하는 데 드는 의료비용을 크게 절감할 수 있습니다. 전 세계 공중보건 캠페인과 예방접종 프로그램은 발병을 억제하고 위험에 처한 집단을 보호하는 데 있으며, 백신의 중요성을 강조하고 있습니다.

세계 보건에 대한 노력은 수막구균 백신 수요에 어떤 영향을 미쳤는가?

세계 보건에 대한 노력은 수막구균 백신에 대한 수요에 큰 영향을 미치고 있습니다. 세계보건기구(WHO)와 세계백신면역연합(GAVI)과 같은 조직이 조정하는 프로그램은 특히 질병 부담이 큰 사하라 사막 이남 아프리카 등 백신 접종이 부족한 지역에서 백신 접종을 늘리는 것을 목표로 하고 있습니다. 목적으로 하고 있습니다. 이러한 노력은 수막구균 백신을 광범위하게 접종하여 질병의 확산을 억제하는 데 도움이 되고 있습니다. 또한 수막염균성 질환의 발생은 집단 예방접종 캠페인이라는 즉각적인 대응을 촉발하는 경우가 많으며, 이는 역학적 추세가 백신 수요에 직접적으로 영향을 미친다는 것을 보여줍니다. 수막염균 감염에 대한 인식이 높아지고 백신의 효능이 입증되면서 개발도상국과 선진국 모두에서 백신 접종을 장려하고 있습니다.

수막염균 백신에 영향을 미치는 과학기술의 발전은 무엇인가?

과학기술의 발전은 수막구균 백신의 효과와 보급률을 높이고 있습니다. 생명공학의 발전으로 결합형 백신의 개발이 가능해져 면역 지속 시간이 길어지고 젊은 연령층에서 더 강한 면역 반응을 얻을 수 있게 되었습니다. 새로운 백신 제제의 연구로 수막염균의 새로운 균주에 대한 방어력이 계속 확대되고 있습니다. 또한 백신 제조 및 보관 기술이 개선되면서 유통망을 확장하고 원격지에도 백신을 보다 효과적으로 전달할 수 있게 되었습니다. 이러한 발전은 특히 자원이 부족한 환경에서 세계 공급망을 유지하고 수막구균성 질환을 퇴치하는 데 필수적인 전체 백신 접종률을 높이는 데 필수적입니다.

수막염균 백신 시장의 성장 원동력은?

수막구균 백신 시장의 성장은 세계 헬스케어 구상 증가, 질병에 대한 인식 증가, 국가 예방접종 프로그램 시행 등 여러 요인에 기인합니다. 백신의 효능과 생산 능력을 향상시키는 기술 발전도 중요한 역할을 합니다. 예방접종률 증가는 전염병 발생에 대한 공중보건 대응과 함께 백신 수요를 더욱 자극하고 있습니다. 또한 백신 연구개발에 대한 정부 재정 지원과 국제적인 지원은 진화하는 병원체 상황에 대응하고 지속적인 적응과 새로운 변종에 대한 방어를 보장하기 위해 매우 중요합니다. 특히 신흥 국가에서는 수막구균 백신에 대한 인식과 의료 인프라가 개선됨에 따라 수막구균 백신에 대한 수요가 증가하여 시장 확대의 원동력이 될 것으로 예상됩니다.

부문

유형(4가, 2가, 기타 유형), 혈청형(A형, B형, C형, W-135형, 기타 혈청형), 연령대(유아(2세 이하), 소아(2세 이상), 성인)

조사 대상 기업의 예(총 42건)

  • Baxter International, Inc.
  • Bio-Med Pvt., Ltd.
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt., Ltd.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSA 25.02.28

Global Meningococcal Vaccines Market to Reach US$5.4 Billion by 2030

The global market for Meningococcal Vaccines estimated at US$4.1 Billion in the year 2024, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Quadrivalent Vaccines, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$3.1 Billion by the end of the analysis period. Growth in the Bivalent Vaccines segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 4.5% CAGR

The Meningococcal Vaccines market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$849.7 Million by the year 2030 trailing a CAGR of 4.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.7% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Meningococcal Vaccines Market - Key Trends & Drivers Summarized

What Are Meningococcal Vaccines, and Why Are They Critical?

Meningococcal vaccines combat the Neisseria meningitidis bacterium, which causes meningitis and other severe infections. These vaccines are crucial public health tools for preventing these potentially deadly diseases, particularly in regions where bacterial meningitis is prevalent. The vaccines are available in different formulations, including those that protect against multiple serogroups of the bacterium, thereby broadening immunity across diverse populations. With meningococcal disease known for its rapid onset and severity, the vaccines not only save lives but also significantly reduce medical costs associated with the treatment of these infections. Public health campaigns and immunization programs worldwide emphasize the importance of these vaccines in controlling outbreaks and protecting at-risk populations.

How Does Global Health Initiatives Influence the Demand for Meningococcal Vaccines?

Global health initiatives significantly influence the demand for meningococcal vaccines. Programs coordinated by organizations such as the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI) aim to increase vaccine access in underserved areas, particularly in sub-Saharan Africa where the disease burden is high. These initiatives help in the widespread administration of meningococcal vaccines, thus controlling the spread of the disease. Moreover, outbreaks of meningococcal disease often prompt immediate responses in terms of mass vaccination campaigns, showcasing the direct impact of epidemiological trends on vaccine demand. The growing awareness of meningococcal disease and the proven effectiveness of vaccines are also driving their uptake in both developing and developed countries.

What Are the Scientific and Technological Progressions Impacting Meningococcal Vaccines?

Scientific and technological progressions are enhancing the effectiveness and reach of meningococcal vaccines. Advances in biotechnology have enabled the development of conjugate vaccines, which offer longer-lasting immunity and a stronger immune response in younger populations. Research into new vaccine formulations continues to expand the protection against additional strains of the meningococcus bacterium. Technological improvements in vaccine production and storage also make it possible to extend the distribution networks, reaching remote areas more effectively. These advancements are critical for maintaining global supply chains, especially in low-resource settings, and improving overall vaccination rates, which are essential for eradicating meningococcal disease worldwide.

What Drives the Growth in the Meningococcal Vaccines Market?

The growth in the meningococcal vaccines market is driven by several factors, including increased global healthcare initiatives, rising awareness of the disease, and the implementation of national immunization programs. Technological advancements that improve vaccine efficacy and production capabilities also play a significant role. The push for higher immunization coverage, combined with public health responses to outbreaks, further stimulates demand for these vaccines. Additionally, government funding and international support for vaccine research and development are crucial for addressing the evolving pathogen landscape, ensuring continued adaptation and protection against new strains. As awareness and healthcare infrastructure improve, particularly in developing nations, the demand for meningococcal vaccines is expected to rise, continuing to drive market expansion.

SCOPE OF STUDY:

The report analyzes the Meningococcal Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Quadrivalent, Bivalent, Other Types); Serotype (Serotype A, Serotype B, Serotype C, Serotype W-135, Other Serotypes); Age Group (Infants (Up to 2 years), Children (Above 2 years) & Adults)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Baxter International, Inc.
  • Bio-Med Pvt., Ltd.
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Meningococcal Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Meningococcal Disease Spurs Demand for Vaccines
    • Advancements in Vaccine Technology Propel Development of New Meningococcal Vaccines
    • Increased Government Funding Enhances Accessibility of Meningococcal Vaccines
    • Global Health Initiatives Boost Immunization Rates for Meningococcal Disease
    • Public Awareness Campaigns Amplify Uptake of Meningococcal Vaccines
    • Expansion of Immunization Programs in Developing Regions Drives Vaccine Adoption
    • Collaborations Between Global Health Bodies and Vaccine Developers Enhance Reach
    • Outbreak Response Strategies Bolster Short-Term Demand for Meningococcal Vaccines
    • Travel Regulations Mandate Meningococcal Vaccination, Driving Market Growth
    • Adult Vaccination Programs Expand Beyond Traditional Pediatric Use
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Meningococcal Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Meningococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Quadrivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Quadrivalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Bivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Bivalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Serotype A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Serotype A by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Serotype B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Serotype B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Serotype C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Serotype C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Serotype W-135 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Serotype W-135 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Serotypes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other Serotypes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Infants (Up to 2 years) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Infants (Up to 2 years) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Children (Above 2 years) & Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Children (Above 2 years) & Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
  • JAPAN
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
  • CHINA
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
  • EUROPE
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Meningococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
  • FRANCE
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
  • GERMANY
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
  • UNITED KINGDOM
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Meningococcal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Type - Quadrivalent, Bivalent and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Meningococcal Vaccines by Type - Percentage Breakdown of Value Sales for Quadrivalent, Bivalent and Other Types for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Serotype - Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Meningococcal Vaccines by Serotype - Percentage Breakdown of Value Sales for Serotype A, Serotype B, Serotype C, Serotype W-135 and Other Serotypes for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Age Group - Infants (Up to 2 years) and Children (Above 2 years) & Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Meningococcal Vaccines by Age Group - Percentage Breakdown of Value Sales for Infants (Up to 2 years) and Children (Above 2 years) & Adults for the Years 2025 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제